JPH0132806B2 - - Google Patents
Info
- Publication number
- JPH0132806B2 JPH0132806B2 JP55045784A JP4578480A JPH0132806B2 JP H0132806 B2 JPH0132806 B2 JP H0132806B2 JP 55045784 A JP55045784 A JP 55045784A JP 4578480 A JP4578480 A JP 4578480A JP H0132806 B2 JPH0132806 B2 JP H0132806B2
- Authority
- JP
- Japan
- Prior art keywords
- quinazolinone
- active
- isopropyl
- chloro
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000013543 active substance Substances 0.000 claims description 36
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- ZWOUXWWGKJBAHQ-UHFFFAOYSA-N fluproquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 ZWOUXWWGKJBAHQ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000036592 analgesia Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 3
- VAFNJIFAZJWWNI-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methoxy-4-phenylquinazolin-2-one Chemical compound O=C1N=C(C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1CC1CC1 VAFNJIFAZJWWNI-UHFFFAOYSA-N 0.000 claims description 2
- HJICZLOIHNWNNY-UHFFFAOYSA-N 8-(4-fluorophenyl)-5-propan-2-yl-[1,3]dioxolo[4,5-g]quinazolin-6-one Chemical compound N=1C(=O)N(C(C)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(F)C=C1 HJICZLOIHNWNNY-UHFFFAOYSA-N 0.000 claims description 2
- FITUMOSFDCKONA-UHFFFAOYSA-N 8-phenyl-5-propan-2-yl-[1,3]dioxolo[4,5-g]quinazolin-6-one Chemical compound N=1C(=O)N(C(C)C)C2=CC=3OCOC=3C=C2C=1C1=CC=CC=C1 FITUMOSFDCKONA-UHFFFAOYSA-N 0.000 claims description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 claims description 2
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 claims description 2
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims 1
- SNEPLIKPVRZUFP-UHFFFAOYSA-N 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-7-methyl-2,1,3-benzothiadiazol-4-amine Chemical compound C12=NSN=C2C(C)=CC(Cl)=C1NC1=NCCN1 SNEPLIKPVRZUFP-UHFFFAOYSA-N 0.000 claims 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 11
- 239000012190 activator Substances 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000007101 Muscle Cramp Diseases 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- -1 quinazolinone compound Chemical class 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000673 doseâresponse relationship Toxicity 0.000 description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- BTCRLDWAIABUCZ-UHFFFAOYSA-N 4-(4-fluorophenyl)-7-methyl-1-propan-2-ylquinazolin-2-one;1h-quinazolin-2-one Chemical compound C1=CC=C2NC(=O)N=CC2=C1.N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 BTCRLDWAIABUCZ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Description
æ¬çºæã¯ãé®ççããã³ç硬çŽè§£é€çã«æŽ»æ§ãª
補å€ã«é¢ããã
é®çå€ãšç硬çŽè§£é€å€ãšã®çµã¿åããã«ã€ããŠ
çš®ã
ã®ææ¡ããªãããŠããããããŠãããšãã°ã
çŒçã®åŠçœ®ã«äœ¿çšãããå€æ°ã®ãã®ãããªè£œå€ã
å
¥æã§ããã
æ¬çºæã«ããã°ãé®ççã«æŽ»æ§ãªãããŸãªãã³
ãšäžæ¢çã«äœçšããç硬çŽè§£é€å€ãäžç·ã«æäžã
ããšãå¢å€§ãããã€æçãªé®ç掻æ§ãªãã³ã«ç硬
çŽè§£é€æŽ»æ§ãåŸãããããšãé©ãã¹ãããšã«ã¯ã
ãŸçºèŠãããã
ããã«è©³ããã¯ãé®ççã«æŽ»æ§ãªãããŸãªãã³
ãšäžæ¢çã«æŽ»æ§ãªç硬çŽè§£é€å€ãäžç·ã«æäžãã
ãšãåã
ã®æåã®åèšããã倧ããé®çå¹åïŒè¶
å ç®ççžå°äœçšïŒãäºæããããããšã«ã¯åŸãã
ãããšãããã€ããçããé©ãã¹ãããšã«ã¯ãé®
ççã«æŽ»æ§ãªãããŸãªãžãã³ã®æäžã¯ãäžç·ã«æ
äžãããäžæ¢çã«æŽ»æ§ãªç硬çŽè§£é€å€ã®æŽ»æ§ã«å
åäœçšãäžããããšãããã€ãããã®äžãããšã
ã°ãã€ãã«ãããŠåè¿°ã®ããã«ãããŸãªãã³ãšç
硬çŽè§£é€å€ãäžç·ã«æäžãããšãç硬çŽè§£é€å€å
ç¬ãæäžãããšãåŸãããçµæã«æ¯ã¹ãŠãè¡æŒ¿äž
ã®ç硬çŽè§£é€å€ã¬ãã«ãäºæãããã»ã©ã«ãã€æ
æã«äžæããïŒçç©æå¹æ§ã®å¢å ïŒããšãããã€
ãã
é®ççã«æŽ»æ§ãªãããŸãªãã³ããã³äžæ¢çã«æŽ»
æ§ãªç硬çŽè§£é€å€ããªãã³ã«ãããã®æåãå«æ
ãã補è¬åŠç補å€ã®å
±æäžã¯ããããããç¡çèŠ
ã®èªçºãããšãã°ãçŒçã®åŠçœ®ã«ããŸãç硬çŽç¶
æ
ã®åŠçœ®ãããšãã°ãçèã®ããçž®ã®åŠçœ®ããã³
çèç·©åã«ãç¹ã«äºæž¬ãããªãå©çããã€ãã®ãš
ããŠæ瀺ãããã該æåã®å
±æäžã¯ãé®çããã³
ç硬çŽè§£é€ã®äž¡æ¹ã®åŠçœ®ãåæã«æ瀺ãããç¶æ
ã®åŠçœ®ã«ãããŠããšã«æåã§ããããšããããã§
ãããã
ããæ
ãæ¬çºæã¯ã
(a) ïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãªãããš
ãã«ïŒâïŒïŒïŒâã¡ãã¬ã³ãžãªãã·âïŒïŒ1HïŒâ
ãããŸãªãã³ïŒïŒâã€ãœãããã«âïŒâããšã
ã«âïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªãã³ïŒïŒ
âã€ãœãããã«âïŒâããšãã«âïŒïŒïŒâã¡ã
ã¬ã³ãžãªãã·âïŒïŒ1HïŒâãããŸãªãã³ïŒïŒâ
ã€ãœãããã«âïŒâïŒïŒâãã«ãªãããšãã«ïŒâ
ïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªãã³ïŒïŒâã·
ã¯ããããã«ã¡ãã«âïŒâããšãã«âïŒâã¡ã
ãã·âïŒïŒ1HïŒâãããŸãªãã³ããã³ïŒâïŒïŒïŒ
ïŒïŒïŒâããªãã«ãªããšãã«ïŒâïŒâããšãã«
âïŒâã¯ããâïŒïŒ1HïŒâãããŸãªãã³ãããª
ã矀ããéžã°ããé®ç掻æ§ãããŸãªãã³åå
ç©ãããã³
(b) ïŒâã¯ããâïŒâã¡ãã«âïŒâïŒïŒâã€ãã
ãŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³
ãŸãã¢ãžã¢ãŸãŒã«ããã³ïŒâã¯ããâïŒâïŒïŒ
âã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒ
ïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ããéžã°ããäžæ¢ç
ã«æŽ»æ§ãªç硬çŽè§£é€ååç©ã
ã掻æ§å€ãšããŠå«æããããšãç¹åŸŽãšããè¬åŠç
調補å€ã§ããã
äžèšé®ç掻æ§ãããŸãªãã³ååç©(a)ã¯ãããšã
ã°ãè±åœç¹èš±æ现æžç¬¬1248430å·ãå第1379677
å·ããã€ãåœå
¬éæ现æž1248430ããã³å2058722
ããäžè¬ã«ç¥ãããŠããããããŠé®çå€ããã³æ
ççå€ãšããŠèšèŒãããŠããã
ãŸããäžèš(b)ã®æŽ»æ§ååç©ã¯ãããšãã°ããã€
ãåœå
¬éæ现æž2800062ãå2653005ããã³å
2416024ãããäžè¬ã«ç¥ãããŠãããååç©ã¯
çš®ã
ã®è¬çåŠç掻æ§ãããšãã°ãç硬çŽè§£é€æŽ»æ§
ãæãããšè¿°ã¹ãããŠããã
æ¬çºæã®çµæç©ã«é¢ããŠè¿°ã¹ããã®ãããªåå
ç©ã®ãã¹ãŠã®éã¯ãéé¢å¡©åºã®éãè¡šãããåæ§
ãªèããééæ¯ã«é©çšãããã
æ¬çºæã«åŸãããšã«å¥œãŸãã補è¬åŠç補å€ã¯ã
次ã®ååç©ãããªãïŒ
(a) é®ççã«æŽ»æ§ãªãããŸãªãã³âïŒâã€ãœãã
ãã«âïŒâïŒïŒâãã«ãªã«ããšãã«ïŒâïŒâã¡ã
ã«âïŒïŒ1HïŒâãããŸãªãã³ãããã³
(b) äžæ¢çã«äœçšããç硬çŽè§£é€å€ãšããŠâïŒâ
ã¯ããâïŒâïŒïŒâã€ãããŸãªã³âïŒâã€ã«ã¢
ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ã
次ã®æ¯æ§ã®ããŒã¿ïŒæ¥æ§ED50ïŒã¯ãæ¬çºæã«
åŸã€ãŠäœ¿çšããååç©ã®ä»£è¡šã§ããã
The present invention relates to analgesically and anisotropically active formulations. Various proposals have been made regarding the combination of analgesics and muscle stiffness relievers, and, for example,
A number of such formulations are available for use in the treatment of pain. In accordance with the present invention, it has surprisingly been found that administration of an analgesically active quinazolinone and a centrally acting muscle anti-rigid agent together results in increased and beneficial analgesic and muscle anti-rigid activity. It has now been discovered. More specifically, when an analgesically active quinazolinone and a centrally active muscle antirigorant are administered together, an analgesic efficacy that is greater than the sum of the individual components (superadditive additive effect) is unexpectedly demonstrated. It turns out that you can get it. Equally surprisingly, administration of an analgesically active quinazolidinone was also found to synergize the activity of a co-administered centrally active muscle antirigorant. Moreover, administering a quinazolinone and an antirigid agent together, as described above, in dogs, for example, results in unexpected levels of the antirigorant in the plasma compared to the results obtained when administering the antirigorant alone. It was found that the bioavailability increased significantly and significantly (increase in biological effectiveness). The co-administration of analgesically active quinazolinones and centrally active muscle analgesics, as well as pharmaceutical preparations containing these ingredients, is therefore useful for the induction of analgesia, e.g. for the treatment of pain, and also for the treatment of muscle pain. It is indicated as having particularly unexpected benefits in the treatment of stiff conditions, such as the treatment of muscle spasm and muscle relaxation. Co-administration of the components will prove particularly useful in the treatment of conditions where both analgesic and muscle relieving treatment are indicated simultaneously. Therefore, the present invention provides (a) 1-isopropyl-4-(4-fluorophenyl)-6,7-methylenedioxy-2(1H)-
Quinazolinone; 1-isopropyl-4-phenyl-7-methyl-2(1H)-quinazolinone; 1
-isopropyl-4-phenyl-6,7-methylenedioxy-2(1H)-quinazolinone; 1-
Isopropyl-4-(4-fluorophenyl)-
7-Methyl-2(1H)-quinazolinone; 1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone and 1-(2,
an analgesically active quinazolinone compound selected from the group consisting of (2,2-trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone; -imidazolin-2-ylamino)-2,1,3-benzothiadiazole and 5-chloro-4-(2
-imidazolin-2-ylamino)-2,1,
This is a pharmaceutical preparation characterized by containing as an active agent a centrally active muscle stiffness relieving compound selected from 3-benzothiadiazole. The analgesically active quinazolinone compound (a) is, for example, British Patent Specification No. 1248430, British Patent Specification No. 1379677.
No. 1248430 and German Publication No. 2058722
It is commonly known from the United States and has been described as an analgesic and anti-inflammatory agent. Moreover, the active compound of (b) above can be used, for example, in German Published Applications No. 2800062, No. 2653005 and No.
2416024, commonly known. The compounds are stated to have various pharmacological activities, such as muscle antirigorizing activity. All amounts of such compounds mentioned with respect to the compositions of this invention represent the amount of free base. Similar considerations apply to weight ratios. Preferred pharmaceutical formulations according to the invention are:
Consists of the following compounds: (a) analgesically active quinazolinone-1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone, and (b) centrally acting As a muscle stiffness release agent -5-
Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole. The following toxicity data (acute ED 50 ) are representative of the compounds used according to the invention.
ãè¡šããtableã
ãè¡šã
æ¬çºæã«åŸã補å€ã¯ãæ®éã®æ¹æ³ã«ãããŠã補
è¬æè¡ãçšããŠèª¿æŽã§ãããããšãã°ãçµæç©
ã¯ã掻æ§å€ã(a)ïŒé®ççã«æŽ»æ§ãªãããŸãªãã³ïŒ
ããã³(b)ïŒäžæ¢çã«äœçšããç硬çŽè§£é€å€ïŒãäž
ç·ã«æ··åããããšã«ãã€ãŠèª¿è£œã§ããããããã¯
å¿
èŠã«å¿ããŠåžžçšã®è£œè¬åŠç賊圢å€ãããšãã°ã
å
å¡«å€ãé ç²å€ã厩å£å€ãçµåå€ã最æ»å€ãåæ£
å€ã湿最å€ãå®å®å€ãææããã³é²è
å€ãšæ··åã§
ããã
æ¬çºæã®è£œå€ã¯é©åœã«åºäœã®åœ¢æ
ãããšãã°ã
é å€ãç²å€ãç²å€ããã³ã«ãã»ã«å€ãŸãã¯æžæ¿æ¶²
ãããã¯ä¹³æ¿æ¶²ã«ããã奜ãŸããã¯ãããã¯åäœ
æäžåœ¢æ
ããšãã«çµå£æäžã®ããã®åäœæäžåœ¢æ
ã«ããããã®ãããªåäœæäžåœ¢æ
ã¯æŽ»æ§å€(a)ãã
ã³(b)ãå¥ã
ã«ãããšãã°ãå±€ç¶ãŸãã¯ãã³ãã«é
å€ãŸãã¯åå²ã«ãã»ã«äžã§å¥ã
ã®å±€ã®åœ¢ã§å«æã§
ããã
ãããã€ãŠãã»ãã®é¢ã«ãããŠãæ¬çºæã¯ãå
è¿°ã®æŽ»æ§å€(a)ãåè¿°ã®æŽ»æ§å€(b)ãšé
åããå¿
èŠã«
å¿ããŠãã®è£œå€ãåäœæäžåœ¢æ
ã«ããããšãããª
ã補è¬åŠç補å€ã®è£œé æ³ãæäŸããã
ããã«ä»ã®é¢ã«ãããŠãæ¬çºæã¯ãåè¿°ã®æŽ»æ§
å€(a)ããã³æŽ»æ§å€(b)ãåæã«æäŸãŸãã¯æäžãã
ããã«é©åãã該掻æ§å€ã¯ããã¯ãŸãã¯ãã€ã¹ã
ã³ãµãŒè£
眮ã«å¥ã
ã«å«æãããŠãããããã¯ãŸã
ã¯ãã€ã¹ãã³ãµãŒè£
眮ãæäŸããã奜é©ã«ã¯ã掻
æ§å€(a)ããã³(b)ã¯ãåé¢ããåäœæäžåœ¢æ
ã§ãã
ã¯ãŸãã¯ãã€ã¹ãã³ãµãŒè£
眮äžã«å«æãããŠã
ãã奜ãŸããã¯ããã¯ãŸãã¯ãã€ã¹ãã³ãµãŒè£
眮
ã¯æŽ»æ§å€(a)ããã³(b)ã®åãã€ãŠæ±ºå®ããéã®åæ
ã®æäžã«ã€ããŠã®æ瀺ãæãããæ瀺ã¯ãããšã
ã°ãããã¯ãŸãã¯è£
眮äžã«çŽæ¥å°å·ã§ããã
åè¿°ã®ããã«ã(a)é®ççã«æŽ»æ§ãªãããŸãªãã³
ããã³(b)äžæ¢çã«äœçšããç硬çŽè§£é€å€ã®çµã¿å
ããã¯ãå¢å€§ããé®ç掻æ§ã瀺ãããã®æŽ»æ§ã®å
èšãããé©ããã»ã©å¹åãããããã®å¹æã¯åç©
ãçšããæšæºã®è©Šéšã«ãããŠãããšãã°ãã©ãã
ã«ã€ããŠè£å©è¬ã®é¢ç¯çã®çŒéè©ŠéšãçšããŠèšŒæ
ã§ããããA.W.Pircio et al.ãEurop.J.of
Pharmacology31ã207â215ïŒ1975ïŒããïŒâã€ãœ
ãããã«âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâã¡
ãã«âïŒïŒ1HïŒâãããŸãªãã³ã®ãããªæŽ»æ§å€(a)
ããã³ïŒâã¯ããâïŒâïŒïŒâã€ãããŸãªã³âïŒ
âã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸ
ãŒã«ã®ãããªæŽ»æ§å€(b)ãããããã1.6ã4.9mgïŒ
Kgããã³2.7ã0.9mgïŒKgã®æäžéã«ãããŠçµã¿å
ãããŠæäžãããšãæäžéã«äŸåããçžå°äœçšã
蚌æãããããã®ãããªè©Šéšã®çµæã¯ãå®æœäŸïŒ
ã«ç€ºãããŠããã
åäžã®çµå£æäžã®æ¥æ§é®çå¹æã®èšåºç 究ã¯ã
çµã¿åãããŠæäžãããšã掻æ§å€(a)ããã³(b)ãå
äžæååç¬ãããé¡èã«ãããã掻æ§ãæããã
ãšããŸã瀺ãã
ïŒã€ãã®ãããªè©Šéšã«ãããŠãåäœæäžéã¯(i)
ïŒmgã®äžæ¢çã«äœçšããç硬çŽç解é€å€ãããšã
ã°ãïŒâã¯ããâïŒâïŒïŒâã€ãããŸãªã³âïŒâ
ã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒ
ã«ã(ii)25mgããã³(iii)100mgã®é®ççã«æŽ»æ§ãªãã
ãŸãªãã³ãããšãã°ãïŒâã€ãœãããã«âïŒâ
ïŒïŒâãã«ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒ
âãããŸãªãã³ããã³(iv)ïŒmgããã³25mgã®ããã
ãç硬çŽè§£é€å€ããã³ãããŸãªãã³ãããªãåäœ
æäžç©ããéçé çãã»ãšãã©ãçåçž®ïŒåŒµåïŒ
é çïŒäžéšåã¯çµåããè管ããã³åŒµåã®é çã
ã®æŽå²ããã€ä»¥å€ã¯å¥åº·ãª48人ã®æ£è
ã«ãäºéç²
æ€ç¡äœçºåéšåç亀ãæ³ïŒpartial crossâover
designïŒãçšããŠãæäžãããå€å
žççé çãæ¢
ç¥ã®è¬ã«å¯Ÿããã¢ã¬ã«ã®ãŒãèè
žç®¡ãå¿èè管ã
èããã³è
ç³»ã®é害ã朰çã®æŽå²ãŸãã¯è¬ã®äŸå
æ§ããã€æ£è
ããã³ïŒæé以å
åã«æåããé®ç
è¬ãé®éå€ãŸãã¯ä»ã®éç¥åæ§è¬ãæããæ£è
ã
æé€ããã
åæ£è
ã¯ïŒçš®ã®åäžã«èŠããè©Šéšæäžç©ã®ïŒçš®
ãåãåãïŒéšåç亀ãæ³ïŒãããŠæäžã®é åºã¯
ç¡äœçºåãããæ£è
ã«ã¯é£äºãããŠããå°ãªããš
ãïŒæéçµéåŸããã ãããªãŸãã¯èããããšã®
ã§ããªã匷ãã§ãªãããäžçšåºŠãŸãã¯æ¿ããé ç
ã®éå§åŸåæäžéãã®ãããã«æ瀺ããã第ïŒå
æ¥ã®æäžã¯ã第ïŒåç®ã®æäžåŸå°ãªããšã24æé
ã«ãããŠè¡ã€ãã
åæ£è
ã«ã¯ãè©ŠéšæäžåŸïŒãïŒããã³ïŒæéã«
ãããŠã(i)èšèªã®ççŽã®å©ãã«ããããããŠ(ii)æ°Ž
å¹³ç·ïŒå¯èŠã®ã¢ããã°ç®çïŒäžã§ãçŒçã®åŒ·ãã
åé¡ããããã«èŠæ±ãããè©Šéšã®åŠçœ®ã«èµ·å ãã
ãšèããããå¯äœçšãèšé²ããã
æšæºã®æè¡ã«åŸãè©Šéšããã®å ±åã®åæã«åºã¥
ããç¡çèŠã®æšå®ã¯ã掻æ§å€(a)ããã³(b)ã®çµã¿å
ãããããªãæäžç©(iv)ã掻æ§å€ãåã
ã«å«æãã
æäžç©(i)ã(ii)ãŸãã¯(iii)ãããããããŠå¹æçãªè¬
ç©ã§ãã€ãããšã瀺ãããã¹ãŠã®è¬ç©ã¯ãã蚱容
ãããå¯äœçšã®åœ±é¿ã¯éåžžã«äœãããã¹ãŠã®ïŒçš®
ã®æäžç©ã®éã«äžèŠåã«ååžããããããã®è©Šéš
ã®çµæãå®æœäŸïŒã«ç€ºãã
掻æ§å€(b)ã®æŽ»æ§ãšæ¯èŒããŠã掻æ§å€(a)ããã³(b)
ïŒããšãã°ãïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãª
ãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªã
ã³ããã³ïŒâã¯ããâïŒâïŒïŒâã€ãããŸãªã³â
ïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢
ãŸãŒã«ïŒã®çµã¿åããã®å¢å€§ããç硬çŽè§£é€æŽ»æ§
ããæšæºã®åç©è©Šéšãããšãã°ãã©ããã®ã¿ãã¢
ãã«ïŒThalomonalïŒç¡¬çŽè©Šéšã«ãããŠèšŒæãã
ããšãã§ãããã®è©Šéšã«ãããŠ7.5mgã®ã¿ãã¢ã
ã«ã泚å°ããŠèªçºãã硬çŽãæå¶ããããšã«ãã
ãåãã€ãŠæäžããçµå£æäžéã®å¹æããªãããŒ
âãã€ãã°ã©ãïŒOffnerâDynographïŒãçšã
ãèšç·Žãã芳å¯è
ã«ãã客芳çã«ççŽã¥ãããã
ã®è©Šéšã«ãããŠãééæ¯ïŒïŒ10ãïŒïŒ50ã(b)ïŒ(a)ã
ã«ãããŠããšãã°ã0.25mgïŒKgäœéã®æŽ»æ§å€(b)ã
äžã®ããã«æŽ»æ§å€(a)ãšçµã¿åãããŠçšãããšãã®
æäžéã«äŸåããæ¹æ³ã®æŽ»æ§ã®å¢å ã¯ã掻æ§å€ã®
çµã¿åããã«ã€ããŠç€ºãããããã®ãããªè©Šéšã®
çµæãå®æœäŸïŒã«ç€ºãã
掻æ§å€(a)ããã³(b)ã®å
±æäžã¯ãç¡çèŠã®èªçºã
ããšãã°ãæè¡åŸã®çŒçããã³é çã®ãããªçç
æ§ãŸãã¯çã¿ãæããç¶æ
ã®åŠçœ®ã«ãããŠããªã
ã³ã«ãç硬çŽç¶æ
ã®åŠçœ®ããšãã°ãçããçž®ã®åŠ
眮ããã³çç·©åã«ãããŠãæçšã§ããã
掻æ§å€(a)ããã³(b)ã®å
±æäžã¯ãçããçž®ããã³
æ¥æ§ã®çã¿ãæããçéªšæ Œã®ç¶æ
ã«é¢é£ããçã¿
ãæããç¶æ
ã®åŠçœ®ãããšãã°ã匵åãŸãã¯çå
çž®ã®é çãæè¡åŸã®çŒçããã³ãªãŠã ããåŠçç¶
æ
ã®åŠçœ®ã«ãããŠãããšã«æçšã§ããã
ãããã€ãŠãªãä»ã®é¢ã«ãããŠãæ¬çºæã¯ãåŠ
眮ãå¿
èŠãšããæ£è
ã«æå¹éã®æŽ»æ§å€(a)ããã³æŽ»
æ§å€(b)ãåè¿°ã®ããã«åæã«æäžããããšãããª
ããæ£è
ã«ãããŠç¡çèŠãèªçºãããã³ïŒãŸãã¯
ç硬çŽç¶æ
ãåŠçœ®ããæ¹æ³ãæäŸããã奜ãŸãã
ã¯æŽ»æ§å€(a)ããã³(b)ã¯çµå£çã«æäžããã
æ¬çºæã®æ¹æ³ã«ãããŠäœ¿çšãã掻æ§å€(a)ããã³
(b)ã®æ£ç¢ºãªïŒæ¥éã¯ããã¡ããã䜿çšããç¹å®ã®
é®ççã«æŽ»æ§ãªãããŸãªãã³ããã³äžæ¢çã«æŽ»æ§
ãªç硬çŽè§£é€å€ããªãã³ã«æäžæ³ããã³åŠçœ®ãã¹
ãç¶æ
ã«äŸåããã
äžè¬ã«å€§ããåºä¹³åç©ã«ã€ããŠãé®çå€ã®æ瀺
ãããïŒæ¥éã¯ç¡çèŠãèªçºããããã«äœ¿çšãã
æšæºã®ïŒæ¥éã®40ã90ïŒ
çšåºŠã§ãããç硬çŽè§£é€
å€ã«ã€ããŠãïŒæ¥éã¯ç硬çŽç¶æ
ã®åŠçœ®ã«äœ¿çšã
ãæšæºã®ïŒæ¥éã®20ã90ïŒ
ã§ããã
é©åœãªæ瀺ãããïŒæ¥éã¯çŽ25ãçŽ600mgã奜
ãŸããã¯çŽ25ãçŽ400mgã®æŽ»æ§å€(a)ã§ããã奜ãŸ
ãã掻æ§å€ïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãª
ãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªã
ã³ãçšãããšãã®å¥œãŸããïŒæ¥éã¯çŽ25ã200mg
ã§ããã
奜é©ã«ã¯æŽ»æ§å€ã¯é
延ãã解æŸã®åœ¢æ
ã§ããã
ãã¯ïŒæ¥ã«ïŒãïŒåã®åå²ããæäžã®åœ¢æ
ã§ãã
ãšãã°ã25ã50ã100ãŸãã¯200mgã®æŽ»æ§å€(a)ãå«
æãããã®ãæäžãããããããã¯ïŒæ¥ïŒåã®æ
äžã§ãããšãã°ã25ãŸãã¯50mgã®æŽ»æ§å€(a)ãå«æ
ãããã®ãæäžããã
掻æ§å€(a)察掻æ§å€(b)ã®æ瀺ãããééæ¯ã¯çŽ
ïŒïŒïŒãçŽ100ïŒïŒã奜ãŸããã¯25ïŒïŒã100ïŒïŒ
ã§ããã奜ãŸãã掻æ§å€ïŒâã€ãœãããã«âïŒâ
ïŒïŒâãã«ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒ
âãããŸãªãã³ã«ã€ããŠããšãã«é©åœãªæ¯ã¯çŽ
10ïŒïŒã奜ãŸããã¯çŽ20ïŒïŒãããã«å¥œãŸããã¯
çŽ25ïŒïŒãçŽ50ïŒïŒã§ãããããã«é©åœãªæ¯ã¯çŽ
10ïŒïŒã奜ãŸããã¯çŽ20ïŒïŒãçŽ30ïŒïŒã§ããã
æã奜ãŸããæ¯ã¯çŽ25ïŒïŒã§ããã
次ã®å®æœäŸã«ããæ¬çºæã«ãããŠäœ¿çšããçµæ
ç©ã«ã€ããŠèª¬æããã
å®æœäŸ ïŒ
çµå£çæäžã«é©ããé å€
äžã«ç€ºãæåãå«æããé å€ã¯ãæ®éã®æè¡ã«
ãã€ãŠè£œé ããããšãã§ãããããŠçŒçããã³ïŒ
ãŸãã¯çããçž®ã®åŠçœ®ã«ãããŠïŒæ¥ïŒåãŸãã¯ïŒ
åçµå£çã«æäžããã®ã«æçšã§ããã
æ å ééïŒmgïŒ
ïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªãã³ 100.00
ïŒâã¯ããâïŒâïŒïŒâã€ãããŸãªã³âïŒâã€ã«
ã¢ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«å¡©
é
žå¡©ïŒïŒ2.0mgå¡©åºïŒ 2.288
ããªãªãã·ãšãã¬ã³ãããã¬ã³éåäœïŒPluronic
F68ïŒ 8.00
ã³ãŒã³ã¹ã¿ãŒã 20.00
ãŒã©ãã³ 12.00
æ©ããããªããã«ãããªãã³ 30.00
ã©ã¯ããŒã¹ 65.712
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã 2.00
240.000
å¿
èŠã«å¿ããŠé å€ã¯ãïŒã€ã«å®¹æã«åå²ã§ãã
ããã«æ圢ã§ããã
å®æœäŸ ïŒ
çµå£çæäžã«é©ããé å€
äžã«ç€ºãæåãå«æããé å€ã¯ãæ®éã®æè¡ã«
ãã€ãŠè£œé ããããšãã§ãããããŠçŒçããã³ïŒ
ãŸãã¯çããçž®ã®åŠçœ®ã«ãããŠïŒæ¥ïŒåãŸãã¯ïŒ
åçµå£çã«æäžããã®ã«æçšã§ããã
æ å ééïŒmgïŒ
ïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªãã³ 50.00
ïŒâã¯ããâïŒâïŒïŒâã€ãããŸãªã³âïŒâã€ã«
ã¢ããïŒâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«å¡©
é
žå¡©ïŒïŒ2.0mgå¡©åºïŒ 2.288
é
ç³é
ž 2.00
ããããã·ãããã«ã»ã«ããŒã¹ 1.70
ããªãªãã·ãšãã¬ã³ãããã¬ã³éåäœïŒPluronic
F68ïŒ 4.00
ãããªãŠã ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ 11.00
ç¡æ°Žã©ã¯ããŒã¹ 40.10
埮å質ã»ã«ããŒã¹ 53.012
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã 0.90
165.00mg
å¿
èŠã«å¿ããŠé å€ã¯ãïŒã€ã«å®¹æã«åå²ã§ãã
ããã«æ圢ã§ããã
å®æœäŸ ïŒ
掻æ§å€(a)ãïŒâã€ãœãããã«âïŒâïŒïŒâãã«
ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸ
ãªãã³ããããã³æŽ»æ§å€(b)ãïŒâã¯ããâïŒâ
ïŒïŒâã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒ
ïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ãã®å
±æäžïŒçž
å°çé®ç掻æ§
è©Šéšã¯åè¿°ã®A.W.Pircio et al.ã®æ¹æ³ã«åŸã€
ãŠå®æœããã掻æ§å€ã®æäžã¯ãé¢ç¯çãèªçºãã
åŠçœ®åŸ16ã18æ¥ã«è¡ã€ããçã¿ã®åå¿ã¯æŽ»æ§å€ã®
æäžåŸïŒæéã«æšå®ããã
ãŸããäžã®æŽ»æ§å€(a)ããã³(b)ã®ED50ïŒãããã
6.5ããã³3.6mgïŒKgïŒãæšå®ããåŒãç¶ããŠåã³
åç¬ã§æäžãã掻æ§å€ã®çžå¯Ÿç掻æ§ãããããã®
ED50å€ã®75ïŒ
ã50ïŒ
ããã³25ïŒ
ã«ãããŠæšå®ã
ããæåŸã«ã75ïŒ
ã50ïŒ
ããã³25ïŒ
ã®æŽ»æ§å€(a)
ãšããããã25ïŒ
ã50ïŒ
ããã³75ïŒ
ã®æŽ»æ§å€(b)ãš
ã®çµã¿åãããçšããŠæŽ»æ§ãæšå®ããã
掻æ§å€ã®çµã¿åããã®æŽ»æ§ã¯ãè¡šã«ç€ºããã
ã«ED50ã«ãããŠæäžããåã
ã®æŽ»æ§ãããèã
ããäžæããïŒè¶
å ç®ççžå°äœçšïŒããšãããã€
ãã[Table] The formulations according to the invention can be prepared in a conventional manner using pharmaceutical technology. For example, the composition may include an active agent, (a) (an analgesically active quinazolinone);
and (b) (centrally acting muscle stiffness relieving agent) can be prepared by mixing together. They may optionally contain conventional pharmaceutical excipients, e.g.
Can be mixed with fillers, granulating agents, disintegrants, binders, lubricants, dispersants, wetting agents, stabilizers, dyes and preservatives. The formulations of the invention are suitably in solid form, e.g.
Form into tablets, powders, granules and capsules or suspensions or emulsions. Preferably they are in unit dosage form, especially for oral administration. Such unit dosage forms can contain the active agents (a) and (b) separately, for example in the form of separate layers in a layered or mantle tablet or split capsule. Accordingly, in another aspect, the present invention provides a pharmaceutical preparation comprising combining the above-mentioned active agent (a) with the above-mentioned active agent (b) and optionally putting this preparation into unit dosage form. A method for manufacturing a formulation is provided. In yet another aspect, the invention is adapted for the simultaneous provision or administration of active agent (a) and active agent (b) as described above, wherein the active agents are contained separately in a pack or dispenser device. , pack or dispenser device. Preferably, active agents (a) and (b) are contained in separate unit dosage forms in a pack or dispenser device. Preferably the pack or dispenser device has instructions for simultaneous administration of predetermined amounts of active agents (a) and (b). The instructions can be printed directly on the pack or device, for example. As mentioned above, the combination of (a) an analgesically active quinazolinone and (b) a centrally acting muscle antirigorant exhibits increased analgesic activity and is surprisingly more potent than the sum of this activity. . This effect can be demonstrated in standard animal tests, for example using the adjuvant arthritic pain test in rats. [AWPircio et al., Europe.J.of
Pharmacology 31 , 207-215 (1975)]. activator (a) such as 1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone;
and 5-chloro-4-(2-imidazoline-2
-ylamino)-2,1,3-benzothiadiazole (b), respectively, from 1.6 to 4.9 mg/
When administered in combination at doses of Kg and 2.7-0.9 mg/Kg, a dose-dependent synergistic effect is demonstrated. The results of such tests are shown in Example 3.
is shown. Clinical studies of the acute analgesic effect of a single oral administration
It is also shown that active agents (a) and (b) when administered in combination have significantly superior activity than the single components alone. In one such test, the unit dose is (i)
1 mg of a centrally acting muscle relaxant, such as 5-chloro-4-(2-imidazoline-2-
ylamino)-2,1,3-benzothiadiazole, (ii) 25 mg and (iii) 100 mg of an analgesically active quinazolinone, e.g. 1-isopropyl-4-
(4-fluorophenyl)-7-methyl-2(1H)
- quinazolinone and (iv) unit doses consisting of 1 mg and 25 mg of muscle antirigorant and quinazolinone, respectively, for non-migraine [mostly muscle contraction (tension)
Headache: Partly combined vascular and tension headache]
A double-blind, randomized, partial cross-over design was conducted on 48 otherwise healthy patients with a history of
design). classic migraine, allergy to known drugs, gastrointestinal tract, cardiovascular,
Patients with hepatic and renal system disorders, history of ulcers or drug dependence and patients with analgesics, sedatives or other sedatives taken within 4 hours previously were excluded. Each patient received two of the four identical-appearing test doses (partial crossover design) and the order of administration was randomized. Patients were instructed to take each dose at least one hour after eating and after the onset of a moderate or severe headache, but not of mild or intolerable intensity. The second dose was administered at least 24 hours after the first dose. Each patient was asked to classify the intensity of pain (i) with the aid of a verbal grade and (ii) on a horizontal line (visible analog scale) at 1, 2 and 3 hours after study administration. did. Any side effects considered to be due to the study treatment were also recorded. Estimation of analgesia based on analysis of reports from tests according to standard techniques indicates that the dose consisting of a combination of active agents (a) and (b) (iv) contains the active agents individually (i) , (ii) or (iii). All drugs were well tolerated and the impact of side effects was very low and irregularly distributed among all four doses. The results of these tests are shown in Example 4. Activators (a) and (b) compared to the activity of activator (b)
(For example, 1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone and 5-chloro-4-(2-imidazoline-
The increased anti-rigidity activity of the combination (2-ylamino)-2,1,3-benzothiadiazole) can also be demonstrated in standard animal tests, such as the rat Thalomonal stiffness test, in which The effect of a pre-administered oral dose in suppressing stiffness induced by injection of 7.5 mg of talomonal is objectively graded by a trained observer using an Offner-Dynograph. In this test, the weight ratio was 1:10 to 1:50 [(b):(a)]
For example, when using 0.25 mg/Kg body weight of active agent (b) in combination with active agent (a) as above, the increase in activity in a dose-dependent manner is shown for the combination of active agents. The results of such tests are shown in Example 5. Co-administration of active agents (a) and (b) induces analgesia;
For example, it is useful in the treatment of inflammatory or painful conditions such as post-surgical pain and headaches, and in the treatment of muscle stiffness conditions, such as the treatment of muscle spasm and muscle relaxation. Co-administration of active agents (a) and (b) is suitable for the treatment of painful conditions associated with muscle spasm and acute painful musculoskeletal conditions, for example tension or muscle contraction headaches, post-surgical pain. It is particularly useful in the treatment of rheumatological conditions. Thus, in yet another aspect, the present invention provides for the treatment of analgesia in a patient in need thereof, comprising administering to the patient in need thereof effective amounts of an active agent (a) and an active agent (b) simultaneously as described above. A method of inducing and/or treating a muscle stiffness condition is provided. Preferably active agents (a) and (b) are administered orally. Active agent (a) used in the method of the invention and
The exact daily dose of (b) will, of course, depend on the particular analgesically active quinazolinone and centrally active antirigorant used, as well as the method of administration and the condition to be treated. Generally, for large mammals, the indicated daily dose of analgesic is on the order of 40-90% of the standard daily dose used to induce analgesia. For muscle stiffness release agents, the daily dose is 20-90% of the standard daily dose used to treat muscle stiffness conditions. A suitable indicated daily dose is about 25 to about 600 mg, preferably about 25 to about 400 mg of active agent (a). When using the preferred active agent 1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone, the preferred daily dose is about 25-200 mg.
It is. Preferably the active agent is administered in delayed release form or in divided doses 2 to 4 times a day, for example containing 25, 50, 100 or 200 mg of active agent (a). or, alternatively, in a single daily dose containing, for example, 25 or 50 mg of active agent (a). The indicated weight ratio of active agent (a) to active agent (b) is from about 5:1 to about 100:1, preferably from 25:1 to 100:1.
It is. Preferred activator 1-isopropyl-4-
(4-fluorophenyl)-7-methyl-2(1H)
- For quinazolinones, particularly suitable ratios are approximately
10:1, preferably about 20:1, more preferably about 25:1 to about 50:1. A more suitable ratio is approximately
10:1, preferably about 20:1 to about 30:1.
The most preferred ratio is about 25:1. The following examples illustrate compositions for use in the present invention. Example 1 Tablets Suitable for Oral Administration Tablets containing the ingredients listed below can be manufactured by conventional techniques and are pain and/or
or once or twice a day in the treatment of muscle spasms.
Useful for oral administration. Component weight (mg) 1-isopropyl-4-(4-fluorophenyl)
-7-Methyl-2(1H)-quinazolinone 100.00 1-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole hydrochloride (=2.0 mg base) 2.288 Polyoxyethylene propylene polymer Pluronic
F68) 8.00 Corn starch 20.00 Gelatin 12.00 Cross-linked polyvinylpyrrolidone 30.00 Lactose 65.712 Magnesium stearate 2.00 240.000 If desired, the tablet can be shaped so that it can be easily divided into two parts. Example 2 Tablets Suitable for Oral Administration Tablets containing the ingredients listed below can be manufactured by conventional techniques and are pain and/or
or once or twice a day in the treatment of muscle spasms.
Useful for oral administration. Component weight (mg) 1-isopropyl-4-(4-fluorophenyl)
-7-Methyl-2(1H)-quinazolinone 50.00 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole hydrochloride (=2.0 mg base) 2.288 Tartaric acid 2.00 Hydroxypropylcellulose 1.70 Polyoxyethylene propylene polymer (Pluronic
F68) 4.00 Sodium carboxymethylcellulose 11.00 Anhydrous lactose 40.10 Fine quality cellulose 53.012 Magnesium stearate 0.90 165.00mg If necessary, the tablet can be shaped so that it can be easily divided into two parts. Example 3 Activator (a) [1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone], and activator (b) [5-chloro-4-
(2-imidazolin-2-ylamino)-2,
Co-administration of [1,3-benzothiadiazole]: additive analgesic activity The test was conducted according to the method of AWPircio et al. described above. Administration of the active agent was carried out 16-18 days after the treatment to induce arthritis. Pain responses were estimated 3 hours after administration of the active agent. First, the ED 50 of the above activators (a) and (b) (respectively
6.5 and 3.6 mg/Kg) and subsequently again the relative activity of the active agent administered alone for each
Estimates were made at 75%, 50% and 25% of the ED50 value. Finally, 75%, 50% and 25% active agent (a)
The activity was estimated using combinations of 25%, 50% and 75% of active agent (b), respectively. The activity of the combination of active agents was found to be significantly elevated (superadditive additive effect) over the activity of each individual administered at ED 50 as shown in the table.
ãè¡šã
å®æœäŸ ïŒ
掻æ§å€(a)ãïŒâã€ãœãããã«âïŒâïŒïŒâãã«
ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸ
ãªãã³ãããã³æŽ»æ§å€(b)ãïŒâã¯ããâïŒâ
ïŒïŒâã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒ
ïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ãã®åç¬ããã³
çµã¿åããã®åäžçµå£æäžã®æ¥æ§é®çå¹æã®èš
åºçç 究
è©Šéšã¯åè¿°ã®æ¹æ³ã«åŸã€ãŠå®æœããã
ç 究ã«åå ãããã¹ãŠã®48人ã®æ£è
ã¯ãããéŠ
å°Ÿããå®çµãããæ£è
ã¯23人ã®ç·ãš25人ã®å¥³ãšã
ããªã€ãŠãããå¹³å幎什ã¯37.9幎ïŒ21ã61æã®ç¯
å²ïŒã§ãããå¹³åäœéã¯65.9KgïŒ48ã99Kgã®ç¯
å²ïŒã§ãã€ãã
èšèªã®ççŽç®çïŒVRSïŒããã³èŠçã¢ããã°
ç®çïŒVASïŒãçšããåæã®çã¿ã®åŒ·ãããã³
æéããšã®çã¿ã®åŒ·ãã®å·®ïŒPIDïŒãæéããšã®
çã¿ã®è§£æŸïŒPARïŒããã³ïŒæéã®ç 究æéã«
ãããåèšã®å¹æïŒSPID VASãSPID VASã
TOTPARïŒã«ã€ããŠã®å¹³åã®ã¹ã³ã¢ãè¡šã«èš
èŒãããPIDïŒVRSããã³VASïŒããã³PARã«
ã€ããŠã®æéâå¹ææ²ç·ã第ïŒå³ã«ããããŠ
SPIDããã³TOTPARã«ã€ããŠã®ãããã第ïŒ
å³ã«ãããããã°ã©ãã§ç€ºãã[Table] Example 4 Activator (a) [1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone] and activator (b) [5-chloro-4-
(2-imidazolin-2-ylamino)-2,
Clinical Study of the Acute Analgesic Effect of Single Oral Administration of 1,3-Benzothiadiazole] Alone and in Combination The study was conducted according to the method described above. All 48 patients participating in the study successfully completed it. The patients consisted of 23 males and 25 females. The mean age was 37.9 years (range 21-61 years), and the mean weight was 65.9 Kg (range 48-99 Kg). Initial pain intensity and hourly pain intensity difference (PID), hourly pain release (PAR) and 3-hour pain intensity using verbal rating scale (VRS) and visual analogue scale (VAS) Total effects over the study period (SPID VAS, SPID VAS,
The average scores for TOTPAR) are listed in the table. The time-effect curves for PID (VRS and VAS) and PAR are shown in Figure 1 and
Second them for SPID and TOTPAR
Each is shown graphically in the figure.
ãè¡šã
å®æœäŸ ïŒ
掻æ§å€(a)ãïŒâã€ãœãããã«âïŒâïŒïŒâãã«
ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸ
ãªãã³ããããã³æŽ»æ§å€(b)ãïŒâã¯ããâïŒâ
ïŒïŒâã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒ
ïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ãã®å
±æäžïŒç
硬çŽè§£é€æŽ»æ§
è©Šéšã¯åè¿°ã®ããã«ããŠå®æœãããè©Šéšããšã«
ïŒå¹ã®ã©ããã䜿çšãããããŠç¡¬çŽã«åã©ããã«
ã€ããŠïŒãïŒã®ç®çã§ççŽã¥ããã
çµæãäžè¡šã«ç€ºãïŒ[Table] Example 5 Activator (a) [1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone], and activator (b) [5-chloro-4 â
(2-imidazolin-2-ylamino)-2,
Co-administration of [1,3-benzothiadiazole]: muscle stiffness relieving activity The test was conducted as described above. Eight rats were used per test, and stiffness was graded for each rat on a scale of 0 to 2. The results are shown in the table below:
第ïŒå³ã¯ãéçé çã®æ£è
ã«ãããæ¥æ§é®çå¹
æïŒ48人ã®æ£è
ãïœïŒ24ïŒè¬å€ã«ãããéšåç亀
ãæ³ïŒã瀺ãã°ã©ãã§ããã第ïŒå³ã¯ãéçé ç
ã®æ£è
ã«ãããïŒæéã®ç 究æéã«ãããå¹æ
ïŒ48人ã®æ£è
ãïœïŒ24ïŒè¬å€ã«ãããéšåç亀ã
æ³ïŒã瀺ãã°ã©ãã§ããã
FIG. 1 is a graph showing the acute analgesic effect in non-migraine patients (48 patients, n=24/drug partial crossover). FIG. 2 is a graph showing the effect over the 3 hour study period in non-migraine patients (48 patients, n=24/partial crossover on drug).
Claims (1)
ããšãã«ïŒâïŒïŒïŒâã¡ãã¬ã³ãžãªãã·âïŒ
ïŒ1HïŒâãããŸãªãã³ïŒïŒâã€ãœãããã«âïŒ
âããšãã«âïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãª
ãã³ïŒïŒâã€ãœãããã«âïŒâããšãã«âïŒïŒ
ïŒâã¡ãã¬ã³ãžãªãã·âïŒïŒ1HïŒâãããŸãªã
ã³ïŒïŒâã€ãœãããã«âïŒâïŒïŒâãã«ãªãã
ãšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâãããŸãªã
ã³ïŒïŒâã·ã¯ããããã«ã¡ãã«âïŒâããšãã«
âïŒâã¡ããã·âïŒïŒ1HïŒâãããŸãªãã³ãã
ã³ïŒâïŒïŒïŒïŒïŒïŒâããªãã«ãªããšãã«ïŒâïŒ
âããšãã«âïŒâã¯ããâïŒïŒ1HïŒâãããŸãª
ãã³ããæã矀ããéžã°ããé®ç掻æ§ãããŸãª
ãã³ååç©ãããã³ (b) ïŒâã¯ããâïŒâã¡ãã«âïŒâïŒïŒâã€ãã
ãŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³
ãŸãã¢ãžã¢ãŸãŒã«ããã³ïŒâã¯ããâïŒâïŒïŒ
âã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒ
ïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ããéžã°ããäžæ¢ç
ã«æŽ»æ§ãªç硬çŽè§£é€ååç©ã ã掻æ§å€ãšããŠå«æããããšãç¹åŸŽãšããå¢å€§ã
ããé®çããã³ç硬çŽè§£é€çšè¬åŠç調補å€ã ïŒ æŽ»æ§ååç©(b)ãïŒâã¯ããâïŒâïŒïŒâã€ã
ããŸãªã³âïŒâã€ã«ã¢ããïŒâïŒïŒïŒïŒïŒâãã³
ãŸãã¢ãžã¢ãŸãŒã«ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®
調補å€ã ïŒ æŽ»æ§ååç©(a)ãïŒâã€ãœãããã«âïŒâïŒïŒ
âãã«ãªãããšãã«ïŒâïŒâã¡ãã«âïŒïŒ1HïŒâã
ããŸãªãã³ã§ãããããŠæŽ»æ§ååç©(b)ãïŒâã¯ã
ãâïŒâïŒïŒâã€ãããŸãªã³âïŒâã€ã«ã¢ããïŒâ
ïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãŸãŒã«ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé ã®èª¿è£œå€ã ïŒ æŽ»æ§ååç©(a)察掻æ§ååç©(b)ã®ééæ¯ã10ïŒ
ïŒã50ïŒïŒã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒ
é ã®èª¿è£œå€ã ïŒ äžèšééæ¯ã25ïŒïŒã50ïŒïŒã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã®èª¿è£œå€ã ïŒ äžèšééæ¯ã25ïŒïŒã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ã®èª¿è£œå€ã ïŒ åäœæäžåœ¢æ ã«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé å
ã¯ç¬¬ïŒé ã®èª¿è£œå€ã ïŒ 25ã50mgã®æŽ»æ§ååç©(a)ãå«æããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®èª¿è£œå€ã[Claims] 1 (a) 1-isopropyl-4-(4-fluorophenyl)-6,7-methylenedioxy-2
(1H)-quinazolinone; 1-isopropyl-4
-phenyl-7-methyl-2(1H)-quinazolinone; 1-isopropyl-4-phenyl-6,
7-methylenedioxy-2(1H)-quinazolinone; 1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1H)-quinazolinone; 1-cyclopropylmethyl-4-phenyl-6- Methoxy-2(1H)-quinazolinone and 1-(2,2,2-trifluoroethyl)-4
-phenyl-6-chloro-2(1H)-quinazolinone, and (b) 5-chloro-7-methyl-4-(2-imidazolin-2-ylamino)-2, 1,3-benzothiadiazole and 5-chloro-4-(2
-imidazolin-2-ylamino)-2,1,
A pharmaceutical preparation for increased analgesia and muscle stiffness relief, characterized in that it contains as an active agent a centrally active muscle stiffness relief compound selected from 3-benzothiadiazole. 2. Preparation according to claim 1, wherein the active compound (b) is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole. 3 Active compound (a) is 1-isopropyl-4-(4
-fluorophenyl)-7-methyl-2(1H)-quinazolinone and the active compound (b) is 5-chloro-4-(2-imidazolin-2-ylamino)-
A preparation according to claim 1 which is 2,1,3-benzothiadiazole. 4 The weight ratio of active compound (a) to active compound (b) is 10:
Claim 1 or 2 which is 1 to 50:1
Preparation agent. 5. The preparation according to claim 4, wherein the weight ratio is from 25:1 to 50:1. 6. The preparation according to claim 5, wherein the weight ratio is 25:1. 7. A preparation according to claim 1 or 2 in unit dosage form. 8. Preparation according to claim 7, containing from 25 to 50 mg of active compound (a).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH341179A CH640415A5 (en) | 1979-04-10 | 1979-04-10 | Therapeutic preparations for the treatment of pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55141413A JPS55141413A (en) | 1980-11-05 |
JPH0132806B2 true JPH0132806B2 (en) | 1989-07-10 |
Family
ID=4255400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4578480A Granted JPS55141413A (en) | 1979-04-10 | 1980-04-09 | Analgesic and muscle stiffness relaxing medicine |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPS55141413A (en) |
AT (1) | AT378916B (en) |
CH (1) | CH640415A5 (en) |
-
1979
- 1979-04-10 CH CH341179A patent/CH640415A5/en not_active IP Right Cessation
-
1980
- 1980-04-09 JP JP4578480A patent/JPS55141413A/en active Granted
- 1980-04-09 AT AT0191680A patent/AT378916B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATA191680A (en) | 1985-03-15 |
CH640415A5 (en) | 1984-01-13 |
JPS55141413A (en) | 1980-11-05 |
AT378916B (en) | 1985-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7687080B2 (en) | Treatment of neuropathy | |
US6444665B1 (en) | Method for treating pain | |
EP0019282B1 (en) | Analgesic mixture of nalbuphine and acetaminophen | |
US20170360798A1 (en) | Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection | |
JP2001527554A (en) | Composition and method for treating neuropathic pain combining antidepressant and NMDA receptor antagonist | |
CZ187097A3 (en) | Pharmaceutical preparation | |
HU219332B (en) | Synergetic medicaments containing trans-(+)-2-[(dimethylamino)-methyl]-1-(3-methoxiphenyl)-cyclohexanol and acetaminophen | |
JP6336592B2 (en) | Pharmaceutical composition for treating pruritus conditions mediated through histamine H4 receptor | |
US20080255079A1 (en) | Therapeutic Use of Nefopam and Analogues Thereof | |
US4694010A (en) | Anticonvulsant compositions and method | |
JPH0157093B2 (en) | ||
PL204075B1 (en) | Tramadol containing pharmacological compositions | |
US6897229B2 (en) | Synergistic combination comprising roflumilast and a PDE-3 inhibitor | |
US4794112A (en) | Acetaminophen/hydroxyzine analgesic combinations | |
EP1603573B1 (en) | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention | |
US4898860A (en) | Anticonvulsant composition and method | |
NO309965B1 (en) | Oral pharmaceutical anti-cough preparation | |
NZ193379A (en) | Analgesic and/or myotonolytic compositions based on an analgesically active quinazolinone and a centrally active myotonolytic | |
EP0027991A1 (en) | Use of combination of compounds for alleviating pain | |
JPH0132806B2 (en) | ||
WO2004080488A2 (en) | Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor | |
US20060079513A1 (en) | Methods and compositions including methscopolamine nitrate | |
FR2787713A1 (en) | COMPOSITION AS A MEDICINAL PRODUCT AND USE OF SUCH A COMPOSITION FOR OBTAINING A MEDICINAL PRODUCT FOR ANESTHESIA, ESPECIALLY ANALGESIC MEDICINAL PRODUCT | |
Hassin-Baer et al. | An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment | |
US4243673A (en) | Analgesic compositions and methods of use |